QNCX.US Quince Therapeutics, Inc.

Healthcare Biotechnology USA Stocks
31.73 USD
Close of Nov 17, 2026
15.10 910.00
Market cap
USD 32.3M
P/E
-
P/B
2.21x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is QNCX.US undervalued?

Graham number

The Graham number of Quince Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Quince Therapeutics, Inc. fundamental analysis

No fundamental analysis for Quince Therapeutics, Inc. yet.

Quince Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device …

Full company profile